Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Tranplantation for Myelofibrosis

Trial Profile

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Tranplantation for Myelofibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Fludarabine (Primary) ; Antithymocyte globulin; Melphalan
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 10 Sep 2012 Planned end date changed from 1 Aug 2011 to 1 Aug 2020 as reported by ClinicalTrials.gov.
    • 24 Jun 2011 Planned end date changed from 1 Aug 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top